The PROMETRIKA team attended the Fierce Biotech Week conference, which offered a front row seat to the evolving landscape of clinical research, where innovation is not just a buzzword but a driving force. The conversations centered around the growing adoption of Risk-Based Quality Management (RBQM) and the ongoing evolution of the Trial Master File (TMF) as a critical tool for inspection readiness. These topics not only dominated sessions and panels, they sparked dynamic roundtable discussions, signaling a shift in how the industry is approaching trial efficiency, compliance and data integrity.
The Importance of RBQM
At the conference, the discussions on RBQM focused on several key best practices for designing and running a clinical trial. Some of the main takeaways from the conference are already being practiced cross-functionally at PROMETRIKA. Our team performs comprehensive risk assessment involving all functional areas to ensure risks are identified and managed consistently and comprehensively. We analyze every step when planning the trial, to identify where potential risks could arise. Our team identifies critical risks early in planning and establishes efforts with the Sponsor on managing these risks effectively, ensuring resources are allocated appropriately, and the project runs smoothly. Integrating risk management into daily operations is PROMETRIKA’s approach, where risk management is not a separate activity but rather it is embedded into everyday processes for continuous monitoring and improvement. Quality is not a department, it’s a culture; a phrase heard during a panel discussion at the conference that genuinely resonated within our company culture and the intentional focus we put forth in our projects.
Quality by design is an indispensable piece of the risk management recipe that is often overlooked and/or misunderstood across departments. A great first step to ensuring your team adopts quality by design requires multifunctional area understanding and awareness of risk management within a team. At PROMETRIKA, we foster this approach by conducting a thorough risk management kick-off meeting where the functional teams are active participants. When you create a fundamental baseline of transparency, you are breeding accountability within your team. Everyone on your team should know which RBQM tool is being used and be encouraged to participate in the identification and mitigation of risks. An effective quality approach actually increases the speed of work. It most certainly takes more effort at the beginning to initiate and establish; however, the results of the hard work are gleamingly evident as the project progresses. PROMETRIKA’s workflow plans for risk assessment meetings to be conducted during a project’s lifecycle.
As clinical research project managers in this industry, we are in the driver’s seat and must pave a path with a quality-by-design mindset with each project. Implementing a project-specific intentional approach to risk management is a key first step. You can tailor the project-specific approach using pillars such as TMF readiness, data integrity, effective trial planning, and operational improvements to support the project’s journey and enhance the trial’s efficiency. Enabling a proactive process within your team will eliminate the reactive action we see so often in our current everyday work that usually is a result of competing priorities or cross-functional teams’ misunderstandings of risk management. Quality-driven projects will allow your team to succeed every time. PROMETRIKA embodies this approach in the day-to-day activities, as well as in the end-to-end clinical trial services we offer. PROMETRIKA promotes effective communication, teamwork and cooperation, ownership and accountability, and flexibility and adaptability that make us flawless in championing quality and success.
Inspection Preparedness Through TMF Management
The conference piqued our interest with discussions on Trial Master File (TMF) inspection readiness. Maintaining TMF is an ongoing process that requires careful planning and involvement across functional areas. The overarching message called attention to establishing a clear TMF plan, identifying the required documents/records, and clearly defining roles and responsibilities as essential parts of inspection readiness. At PROMETRIKA, we utilize Medidata eTMF as our centralized eTMF system. This helps us adhere to compliance with data security and privacy regulations. This centralized eTMF system also allows us to use our customized project TMF plan. The system houses documents that are collected and stores them in real time, is user friendly, and has access control. Overall, centralized eTMF systems allow for better automated oversight with availability of audit trails and various reports.
During the startup phase of a project, PROMETRIKA conducts a meeting with the functional team to align on the project specific eTMF plan, centralized system, and expectations. A project-specific storyboard is created that is easily accessible by the project team and provides a wholistic picture of the project-specific TMF status. The storyboard also helps identify any gaps or missing documents. Routine quality checks are performed on the eTMF, led by PROMETRIKA’s subject matter experts. These QC’s solicit project-specific functional leads’ reviews and input.
TMF is a key component of a trial as it serves as the official record of how the trial was conducted and managed. With regulatory scrutiny increasing along with the volume of TMF documents, having a simplified yet effective method is critical. It starts with a well-developed TMF plan. Tools can be tailored to support efficiencies and compliance while maintaining the eTMF. Remember to celebrate the wins! Clean inspections indicate patient safety is at the forefront, ensuring a successful trial. The PROMETRIKA way empowers the team to ensure inspection readiness at all times by implementing best practices and utilizing an integrated eTMF system.
As it is throughout the industry, PROMETRIKA’s aims are patient safety, actionable data, and sound science to support the development of new treatments. Our early adoption and continual improvement of RBQM and eTMF planning and execution help us achieve these aims.
